Categories
Credit Cards

Merrill Lynch Stick to Their Buy Rating for CVS Health Corp

Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of eighty three dolars, which is approximately 9.11 % above the present share price of $76.07.

Cherny expects CVS Health Corp to submit earnings per share (EPS) of $0.93 for the first quarter of 2021.

The present consensus among 11 TipRanks analysts is for a reasonable Buy rating of shares in CVS Health, with an average price goal of eighty four dolars.

The analysts priced targets range from a high of hundred one dolars to a low of $61.

From its latest earnings report, released on 09/30/2020, the company found a quarterly revenue of $67.06 billion and a net profit of $3.25 billion. The company’s market cap is $99.57 billion.

According to TipRanks.com, Merrill Lynch analyst Michael Cherny is now ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 11.5 % and a 60.53 % success rate.

CVS Health Corp. engages in the provision of health care services. It runs through the following segments: Pharmacy Services, Long or retail Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment provides pharmacy benefit management solutions. The Long or retail Term Care segment includes selling of prescription drugs and assortment of general merchandise.

The Health Care Benefits segment offers quite traditional, voluntary and consumer-directed health insurance products as well as associated services, which includes medical, pharmacy, dental, behavioural health, medical management abilities. The Corporate segment involves in providing administrative services and management. The company was developed by Stanley P. Goldstein and Ralph Hoagland in 1963 and it is headquartered in Woonsocket, RI.

Leave a Reply

Your email address will not be published. Required fields are marked *